These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8775567)

  • 1. Kawasaki disease and human parvovirus B19 antibody: role of immunoglobulin therapy.
    Fukushige J; Takahashi N; Ueda K; Okada K; Miyazaki C; Maeda Y
    Acta Paediatr Jpn; 1995 Dec; 37(6):758-60. PubMed ID: 8775567
    [No Abstract]   [Full Text] [Related]  

  • 2. Kawasaki disease associated with parvovirus B19 infection.
    Holm JM; Hansen LK; Oxhøj H
    Eur J Pediatr; 1995 Aug; 154(8):633-4. PubMed ID: 7588963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active or recent parvovirus B19 infection in children with Kawasaki disease.
    Nigro G; Zerbini M; Krzysztofiak A; Gentilomi G; Porcaro MA; Mango T; Musiani M
    Lancet; 1994 May; 343(8908):1260-1. PubMed ID: 7910278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease.
    Shrestha S; Wiener HW; Olson AK; Edberg JC; Bowles NE; Patel H; Portman MA
    J Allergy Clin Immunol; 2011 Sep; 128(3):677-80. PubMed ID: 21601260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome.
    Kerr JR; Cunniffe VS; Kelleher P; Bernstein RM; Bruce IN
    Clin Infect Dis; 2003 May; 36(9):e100-6. PubMed ID: 12715326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of association between Kawasaki syndrome and infection with parvovirus B19, human herpesvirus 8, TT virus, GB virus C/hepatitis G virus or Chlamydia pneumoniae.
    Chua PK; Nerurkar VR; Yu Q; Woodward CL; Melish ME; Yanagihara R
    Pediatr Infect Dis J; 2000 May; 19(5):477-9. PubMed ID: 10819350
    [No Abstract]   [Full Text] [Related]  

  • 7. Reduced serologic response to mumps, measles, and rubella vaccination in patients treated with intravenous immunoglobulin for Kawasaki disease.
    Tacke CE; Smits GP; van der Klis FR; Kuipers IM; Zaaijer HL; Kuijpers TW
    J Allergy Clin Immunol; 2013 Jun; 131(6):1701-3. PubMed ID: 23498596
    [No Abstract]   [Full Text] [Related]  

  • 8. Seroprevalence of human herpesvirus 7 in patients with Kawasaki disease.
    Burns JC; Newburger JW; Sundell R; Wyatt LS; Frenkel N
    Pediatr Infect Dis J; 1994 Feb; 13(2):168-9. PubMed ID: 8190553
    [No Abstract]   [Full Text] [Related]  

  • 9. Positive hepatitis serologies with treatment for Kawasaki syndrome.
    Borowitz SM
    Arch Dis Child; 1993 Jan; 68(1):151. PubMed ID: 8435007
    [No Abstract]   [Full Text] [Related]  

  • 10. Absence of parvoviral genomes in endothelial cells of Kawasaki disease patients with coronary artery lesions.
    Bowles NE; Hirono K; Yu X; Ichida F
    Pediatr Infect Dis J; 2009 Apr; 28(4):345. PubMed ID: 19238110
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of immunoglobulin retreatment in Kawasaki disease.
    Falcini F; Ermini M; Trapani S; Taccetti G
    J Pediatr; 1994 Oct; 125(4):672-3. PubMed ID: 7931898
    [No Abstract]   [Full Text] [Related]  

  • 12. Adult Kawasaki disease: evaluating the fluctuation of circulating lymphocytes associated with i.v. immunoglobulin treatment.
    Fujimoto N; Teramura K; Tanaka T
    J Dermatol; 2012 Nov; 39(11):957-8. PubMed ID: 22390144
    [No Abstract]   [Full Text] [Related]  

  • 13. Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome.
    Shiraishi T; Yamamoto T
    Pediatr Dermatol; 2013; 30(3):e30-1. PubMed ID: 22304420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The treatment of Kawasaki disease.
    Sagraves R
    J Pediatr Health Care; 1993; 7(6):278-82. PubMed ID: 8106928
    [No Abstract]   [Full Text] [Related]  

  • 15. The immunoregulatory effects of IVIG in Kawasaki disease and other autoimmune diseases.
    Leung DY
    Clin Rev Allergy; 1992; 10(1-2):93-104. PubMed ID: 1606527
    [No Abstract]   [Full Text] [Related]  

  • 16. Paradoxical response to intravenous immunoglobulin in a case of Parvovirus B19-associated chronic fatigue syndrome.
    Attard L; Bonvicini F; Gelsomino F; Manfredi R; Cascavilla A; Viale P; Varani S; Gallinella G
    J Clin Virol; 2015 Jan; 62():54-7. PubMed ID: 25542471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kawasaki disease in Calcutta.
    Paul DK; Gupta A; Lahiri M
    Indian Pediatr; 2000 Nov; 37(11):1264-5. PubMed ID: 11086312
    [No Abstract]   [Full Text] [Related]  

  • 18. Kawasaki disease--treatment with intravenous immunoglobulin during the acute stage.
    Singh S; Kumar L
    Indian Pediatr; 1996 Aug; 33(8):689-92. PubMed ID: 8979554
    [No Abstract]   [Full Text] [Related]  

  • 19. Resistance to intravenous immunoglobulin (IVIG) in Kawasaki disease: no influence of different IVIG lot utilisation.
    Pagnini I; Marino A; Simonini G; Cimaz R
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S170. PubMed ID: 22410254
    [No Abstract]   [Full Text] [Related]  

  • 20. Chronic human parvovirus B19 infection associated with interstitial lung disease.
    Klar A; Halamish A; Shoseyov D; Cassinotti P; Siegl G; Springer C; Shazberg G; Hurvitz H
    Isr Med Assoc J; 2002 Oct; 4(10):825-6. PubMed ID: 12389353
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.